 |
245 Diseases |  |
389 Trials |
|
389 Trials |  |
11400 News |  |
| «12...96979899100101102103104105106...143144» |
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
AXL mediates cetuximab resistance through tyrosine 821 and activation of c-Abl kinase in head and neck cancer (Board 128: Level 2 - Hall D) - Sep 18, 2019 - Abstract #AACRNCIEORTC2019AACR_NCI_EORTC_167;
Collectively, the studies presented herein suggest that tyrosine 821 of AXL mediates resistance to cetuximab by activation of c-Abl in HNSCC and targeting both EGFR and c-Abl leads to a robust anti-tumor response. These results provide rationale for the clinical targeting of c-Abl to enhance the therapeutic modalities used in treating HNSCC.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Comparative analysis of proteomic/transcriptomic profiles of a panel of GC-PDXs (Board 25: Level 2 - Hall D) - Sep 18, 2019 - Abstract #AACRNCIEORTC2019AACR_NCI_EORTC_59;
We previously described establishment of a panel of GC-PDX with transcriptome annotation and utilized these models for biomarker discovery predictive of the cetuximab response (Zhang et al., 2013)...The variability of protein abundance can be partially explained by mRNA level, however, post-transcriptional regulation could play important role on protein expression especially for highly transcribed genes. Proteomics data may provide complimentary information to transcriptome data for predictive biomarker analysis.
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Association of Primary Tumor Site With Mortality in Patients Receiving Bevacizumab and Cetuximab for Metastatic Colorectal Cancer. (Pubmed Central) - Sep 18, 2019
In patients with wild-type KRAS tumors, treatment with cetuximab benefited only those with left-sided mCRC and was associated with significantly poorer survival among those with right-sided mCRC. Our results underscore the importance of stratification by tumor site for current treatment guidelines and future clinical trials.
- ||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Gilotrif (afatinib) / Boehringer Ingelheim
When I went to your site and searched for “egfr” in Lung Cancer search, there was only 1 study of Afatinib and cetuximab. Not very impressive. (Twitter) - Sep 18, 2019
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Journal: Induction of anaplastic lymphoma kinase (ALK) as a novel mechanism of EGFR inhibitor resistance in head and neck squamous cell carcinoma patient-derived models. (Pubmed Central) - Sep 18, 2019
Four different ALK inhibitors, including two (ceritinib and brigatinib) FDA approved for lung cancer, were effective in combination with gefitinib. Together, we identified induction of ALK by EGFR inhibitor as a novel mechanism potentially relevant to resistance to EGFR inhibitor, a high ratio of response of HNSCC patient-derived tumor cells to a combination of ALK and EGFR inhibitors, and applicability of repurposing ALK inhibitors to HNSCC that lack ALK aberrations.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Inhibition of JAK1 sensitizes human head and neck cancer cells to cetuximab (Exhibition area) - Sep 17, 2019 - Abstract #ESMOAsia2019ESMO_ASIA_665;
It is currently used in combination with radiation or chemotherapy for these patients. The results reported herein suggest that the anti-proliferative effects of cetuximab can be enhanced with the addition of JAK1 inhibition.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Survival outcomes and survival predictors in recurrent and metastatic head and neck squamous cell cancer (R/M-HNSCC) patients treated with chemotherapy (CT) plus cetuximab as first-line therapy in a real-world study (Exhibition area) - Sep 17, 2019 - Abstract #ESMOAsia2019ESMO_ASIA_654;
2008). ECOG PS, larynx/hypopharynx location and skin toxicity related to Cetuximab could be used to define pt prognosis.Legal entity responsible for the study: The authors.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Severe hypovitaminosis D in metastatic gastric cancer patients from the Northern and Southern hemispheres: Data from the EXPAND phase III trial (Exhibition area) - Sep 17, 2019 - Abstract #ESMOAsia2019ESMO_ASIA_511;
P3
However, the majority of patients with metastatic gastric cancer have a severe vitamin D deficiency with only minor differences comparing Southern versus Northern hemisphere of residency.Legal entity responsible for the study: Masaryk Memorial Cancer Institute. Funding: Masaryk Memorial Cancer Institute, University Leipzig.
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical significance and converionrate relevance of RAS genetic mutation analysis for unresectable colorectal liver metastases: A single-center retrospective study (Exhibition area) - Sep 17, 2019 - Abstract #ESMOAsia2019ESMO_ASIA_486;
RAS wild type indicated a better conversion rate for patients with initially unresectable colorectal liver metastases.Legal entity responsible for the study: The authors. Funding: Has not received any funding.
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Contrast-enhanced CT-based textural parameters as potential prognostic factors of survival for colorectal cancer patients receiving targeted therapy (Exhibition area) - Sep 17, 2019 - Abstract #ESMOAsia2019ESMO_ASIA_473;
In conclusion, our study provides preliminary evidences that several radiomic parameters of tumor lesions derived from CT images were prognostic factors and predictive markers for CRC patients who are candidates for targeted therapy (bevacizumab and cetuximab).Legal entity responsible for the study: The authors. Funding: Has not received any funding.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Biomarker selection of liver metastatic colorectal patients for anti-EGFR monoclonal antibodies: A machine learning analysis (Exhibition area) - Sep 17, 2019 - Abstract #ESMOAsia2019ESMO_ASIA_463;
Ten new predictive mutations help to refine the selection of RAS and BRAF wild-type metastatic colorectal cancer patients candidates for anti-EGFRs.Legal entity responsible for the study: Zhongshan Hospital. Funding: The National Natural Science Foundation of China.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
A novel anti-EGFR antibody HLX07 for potential treatment of squamous cell carcinoma of the head and neck (Exhibition area) - Sep 17, 2019 - Abstract #ESMOAsia2019ESMO_ASIA_438;
P1, P1/2
These findings support the initiation of a phase 1b/2 study of HLX07 plus chemotherapy in advanced solid tumours with the longest follow-up time of over 275 days as of 20-June-2019. Additionally, HLX07 is currently under safety and efficacy investigation combined with anti-PD-1 antibody, HLX10, in squamous cell carcinoma of head and neck.Legal entity responsible for the study: Shanghai Henlius Biotech, Inc.; Taiwan Henlix Biotech Co., Ltd.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Survival outcomes and prognostic factors in recurrent and/or metastatic head and neck cancer patients treated with chemotherapy plus cetuximab as first-line therapy in a real-world setting (Room 324) - Sep 17, 2019 - Abstract #ESMOAsia2019ESMO_ASIA_331;
2008). At baseline, ECOG PS, larynx/hypopharynx location and skin toxicity related to Cetuximab could be used to define pt prognosis.Legal entity responsible for the study: The authors.
- Keytruda (pembrolizumab) / Merck (MSD), Erbitux (cetuximab) / Eli Lilly, EMD Serono
Phase III KEYNOTE-048 study of first-line pembrolizumab for recurrent/metastatic head and neck squamous cell carcinoma: Asia vs non-Asia subgroup analysis (Hall 404) - Sep 17, 2019 - Abstract #ESMOAsia2019ESMO_ASIA_305;
P3
Pembro + chemo vs E showed favorable OS in patients with CPS ≥20 in Asia and non-Asia subgroup regardless of PD-L1 status, durable responses, and similar safety.Legal entity responsible for the study: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. Funding: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, sEphB4-HSA / VasGene, National Cancer Institute
New P1 trial, Combination therapy, Metastases: sEphB4-HSA With RT+Chemo or Cetux in Patients With Intermediate to High Risk LAHNSCC (clinicaltrials.gov) - Sep 17, 2019
P1, N=30, Not yet recruiting, Sponsor: University of Colorado, Denver
- | Zaltrap (ziv-aflibercept IV) / Sanofi, Regeneron, Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Review, Journal, IO Biomarker: A Comprehensive Review of Sequencing and Combination Strategies of Targeted Agents in Metastatic Colorectal Cancer. (Pubmed Central) - Sep 16, 2019
We review the latest clinical data that support the utilization of several targeted agents alone or in combination with backbone chemotherapy across different lines of treatment and patient populations and highlight recommendations for their usage. Recent advances in the treatment landscape are also summarized, including genomic profiling and preliminary results with immune checkpoint inhibitors.
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, P2 data, Journal: Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical Trial. (Pubmed Central) - Sep 16, 2019
P2
Although neither of the 2 arms met the primary end point, the findings indicate that a 4-month induction regimen of mFOLFOXIRI plus cetuximab is feasible and provides relevant activity results, leading to a high surgical resection rate. clinicaltrials.gov Identifier: NCT02295930.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, P3 data, Journal: Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The Open-Label, Randomized, Phase III TAILOR Trial. (Pubmed Central) - Sep 16, 2019
P3
Treatment was well tolerated, and there were no new or unexpected safety findings. Conclusion The TAILOR study met all of its objectives and relevant clinical end points, confirming cetuximab in combination with FOLFOX as an effective standard-of-care first-line treatment regimen for patients with RAS wt mCRC.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal, Combination therapy, IO Biomarker: A potential therapy for chordoma via antibody-dependent cell-mediated cytotoxicity employing NK or high-affinity NK cells in combination with cetuximab. (Pubmed Central) - Sep 14, 2019
RESULTS Here the authors demonstrate for the first time 1) that cetuximab in combination with NK cells can mediate ADCC of chordoma cells; 2) the influence of the NK CD16 polymorphism in cetuximab-mediated ADCC for chordoma cell lysis; 3) that engineered haNK cells-that is, cells transduced to express the CD16 V158 FcγRIIIa receptor-bind cetuximab with similar affinity to normal NK cells expressing the high-affinity VV allele; and 4) that irradiated haNK cells induce ADCC with cetuximab in chordoma cells. CONCLUSIONS These studies provide rationale for the use of cetuximab in combination with irradiated haNK cells for therapy for chordoma.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Biomarker, Clinical, P3 data, Journal: Biomarker-Stratified Phase III Clinical Trials: Enhancement with a Subgroup-Focused Sequential Design. (Pubmed Central) - Sep 14, 2019
We also provide an application to SWOG S0819, a trial to assess the role of cetuximab in treating non-small cell lung cancers...We also provide an application to SWOG S0819, a trial to assess the role of cetuximab in treating non-small cell lung cancers. These evaluations indicate that the proposed subgroup-focused approach can enhance the efficiency of the marker-stratified design for definitive evaluation of treatment and biomarker in phase III clinical trials.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Biomarker, Retrospective data, Journal, Mismatch Repair: Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials. (Pubmed Central) - Sep 14, 2019
P3
The prognostic impact of DNA mismatch repair (MMR) status in stage III colon cancer patients receiving FOLFOX (folinic acid, fluorouracil, and oxaliplatin) adjuvant chemotherapy remains controversial...Patients in the clinical trials were randomly assigned to receive 6 months of chemotherapy with FOLFOX or FOLFOX plus cetuximab...The deficient MMR phenotype remains a favorable prognostic factor in patients with stage III colon cancer receiving FOLFOX adjuvant chemotherapy. clinicaltrials.gov Identifier: NCT00079274 for the NCCTG N0147 trial and EudraCT identifier: 2005-003463-23 for the PETACC8 trial.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: NKG2D Immunoligand rG7S-MICA Enhances NK Cell-mediated Immunosurveillance in Colorectal Carcinoma. (Pubmed Central) - Sep 14, 2019
However, cetuximab, as one of the first-line targeted drugs in the treatment of CRC, has drug resistance and poor prognosis in clinic...Furthermore, in a CD24 CRC-bearing nude mice model, rG7S-MICA effectively recruits NK cell to the tumor site and increase the release of cytokines such as interferon-γ (IFN-γ) and tumor necrosis factor-α (TNF-α), and shows potential antitumor effects. In conclusion, rG7S-MICA provides a novel immunotherapeutic strategy for CRC, which could be further developed against other CD24 malignancies.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Journal: Comparing outcomes of concurrent chemotherapy regimens in patients 65 years or older with locally advanced oropharyngeal carcinoma. (Pubmed Central) - Sep 14, 2019
Patients who received CDDP had improved OS. CDDP was also associated with slightly lower overall costs and higher antiemetic usage and hospital visit rates, although a strong selection bias was observed because those receiving CTX and carboplatin were older and had higher comorbidity scores.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Reimbursement, Journal, Medicare: Survival of patients with head and neck cancer treated with definitive radiotherapy and concurrent cisplatin or concurrent cetuximab: A Surveillance, Epidemiology, and End Results-Medicare analysis. (Pubmed Central) - Sep 14, 2019
These results suggest that cisplatin may be the preferred chemotherapeutic agent in this setting. Cancer 2018;124:000-000.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Journal, Real-World Evidence: Predictive and prognostic implications of 4E-BP1, Beclin-1, and LC3 for cetuximab treatment combined with chemotherapy in advanced colorectal cancer with wild-type KRAS: Analysis from real-world data. (Pubmed Central) - Sep 14, 2019
The effect of cetuximab on colon cancer cells might be improved by autophagy. LC3 is overexpressed in tumor tissues, and Beclin1 and 4E-BP1 could be significant predictors of OS in ACRC patients treated with cetuximab.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: New fluorine-18 pretargeting PET imaging by bioorthogonal chlorosydnone-cycloalkyne click reaction. (Pubmed Central) - Sep 13, 2019
The injection of a fluorine-18 labeled cyclooctyne three days after cetuximab bearing chlorosydnone moieties allowed a significant detection of the tumor by PET imaging suggesting an efficient click reaction inside the tumoral site. With a kinetic constant superior to 300 M-1 s-1, the SPSAC reaction might be an interesting tool, in addition to tetrazine-cyclooctene ligation, for in vivo chemistry.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Cetuximab in the management of nasopharyngeal carcinoma - a narrative review. (Pubmed Central) - Sep 13, 2019
There is more promise for its use in metastatic or locally recurrent settings. This review draws together the existing evidence and could provide a focus for future studies.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Biomarker, Clinical, Journal: Tumor sidedness and enriched gene groups for efficacy of first-line cetuximab treatment in metastatic colorectal cancer. (Pubmed Central) - Sep 12, 2019
In conclusion, genes contributing to the efficacy of cetuximab treatment may differ according to the sidedness in mCRC. NOTCH1 may potentially discriminate favorable responders to cetuximab in patients with left-sided tumors.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion: Combination of Cetuximab and NK Immunotherapy for Recurrent Non-small Cell Lung Cancer (clinicaltrials.gov) - Sep 12, 2019
P1/2, N=30, Completed, Sponsor: Fuda Cancer Hospital, Guangzhou
NOTCH1 may potentially discriminate favorable responders to cetuximab in patients with left-sided tumors. Recruiting --> Completed
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Primary analysis results of randomized controlled trial evaluating reactive topical corticosteroid strategies for the facial acneiform rash by EGFR inhibitors (EGFRIs) in patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC): FAEISS study (Bilbao Auditorium (Hall 5)) - Sep 11, 2019 - Abstract #ESMO2019ESMO_3782;
It would follow that minocycline and heparinoid moisturizer have a prophylactic efficacy while topical corticosteroids have a therapeutic efficacy for facial acneiform rash. Clinical trial identification: UMIN000024113.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer, Mektovi (binimetinib) / Ono Pharma, Pierre Fabre, Pfizer
Encorafenib plus cetuximab with or without binimetinib for BRAF V600E–mutant metastatic colorectal cancer: Expanded results from a randomized, 3-arm, phase III study vs the choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC) (Barcelona Auditorium (Hall 2)) - Sep 11, 2019 - Abstract #ESMO2019ESMO_3487;
P3
Data suggest that the triplet offers improved efficacy vs doublet with some additional manageable toxicity and no impact on overall QOL. Further follow-up will better define the relative benefits of the regimens.
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Genetic variants in the one-carbon metabolism pathway to predict outcome in patients with metastatic colorectal cancer (mCRC): Data from TRIBE and FIRE-3 phase III trials (Tarragona Auditorium (Hall 7)) - Sep 11, 2019 - Abstract #ESMO2019ESMO_3357;
These findings may provide novel perspectives on the role of 1CM signaling in CRC and possibly contribute to open novel therapeutic options. Legal entity responsible for the study: The authors.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, buparlisib (BKM120) / Novartis, Adlai Nortye
Buparlisib (BKM120) in refractory head and neck squamous cell carcinoma harbouring or not a PI3KCA mutation: A phase II multicenter trial (Bilbao Auditorium (Hall 5)) - Sep 11, 2019 - Abstract #ESMO2019ESMO_3256;
P2
Clinical trial identification: NCT01737450. Legal entity responsible for the study: Centre Léon Bérard.
- Bavencio (avelumab) / EMD Serono, Pfizer, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Avelumab-cetuximab-radiotherapy versus standards of care (SoC) in patients (pts) with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): Safety phase of randomized trial GORTEC 2017-01 (REACH) (Bilbao Auditorium (Hall 5)) - Sep 11, 2019 - Abstract #ESMO2019ESMO_3254;
P3
Clinical trial identification: NCT02999087. Legal entity responsible for the study: GORTEC.
- Keytruda (pembrolizumab) / Merck (MSD), Erbitux (cetuximab) / Eli Lilly, EMD Serono
Pembrolizumab and radiotherapy for locally advanced head and neck squamous cell carcinoma (LA-HNSCC) with contraindication to cisplatin therapy (Bilbao Auditorium (Hall 5)) - Sep 11, 2019 - Abstract #ESMO2019ESMO_3253;
P2
Pembrolizumab does not potentiate typical XRT associated toxicities and no unexpected immune related adverse events were observed. Further, lower rates of feeding tube placement and grade 3/4 dermatitis, xerostomia, and mucositis were noted when compared to RTOG1016 (concurrent XRT with cisplatin or cetuximab in LA-HNSCC).
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Analysis of efficacy outcomes based on programmed death ligand 1 (PD-L1) scoring techniques in patients with head and neck squamous cell carcinoma (HNSCC) from KEYNOTE-040 (Bilbao Auditorium (Hall 5)) - Sep 11, 2019 - Abstract #ESMO2019ESMO_3251;
P3
At higher expression levels, CPS ≥50 can be used interchangeably with TPS ≥50%. Thus, CPS is a valid scoring method for determining PD-L1 status in patients with HNSCC being evaluated for second-line treatment.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Cisplatin reduces costs and provides more quality adjusted life years (QALYs) than cetuximab in chemoradiotherapy for patients with HPV-positive oropharyngeal cancer (HPV+OPC) (Cordoba Auditorium (Hall 7)) - Sep 11, 2019 - Abstract #ESMO2019ESMO_3207;
P3
Clinical trial identification: NCT01874171. Legal entity responsible for the study: Hisham Mohamed Mehanna.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Personalized treatment according to geriatric assessment in first-line recurrent and/or metastatic (R/M) head and neck squamous cell cancer (HNSCC) patients aged 70 or over: ELAN (ELderly heAd and Neck cancer) FIT and UNFIT trials (Cordoba Auditorium (Hall 7)) - Sep 11, 2019 - Abstract #ESMO2019ESMO_3206;
P2, P3
For unfit elderly pts, there was no efficacy difference of Cx and MTX. PS ECOG 2 pts did not benefit from systemic treatment.
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Next-generation sequencing (NGS) in metastatic colorectal cancer (mCRC): Novel mutated genes and their effect on response to therapy (Alliance) (Barcelona Auditorium (Hall 2)) - Sep 11, 2019 - Abstract #ESMO2019ESMO_3151;
P3
It provides novel gene candidates affecting response to Bev and Cet, each combined with chemotherapy, as well as mutated genes affecting the prognosis of patients. If validated in other phase III studies, these results may be used to guide treatment decisions in pts with mCRC.
- ASP-1929 / Rakuten Aspyrian, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Intratumoral and peripheral exploratory biomarker analysis in patients with locoregional, recurrent head and neck squamous cell carcinoma (rHNSCC) treated with RM-1929 photoimmunotherapy (Poster Area (Hall 4)) - Sep 11, 2019 - Abstract #ESMO2019ESMO_2886;
P1/2, P3
Further evaluation of these biomarkers will be conducted in a Phase 3 trial (NCT03769506). Clinical trial identification: NCT02422979.
- ASP-1929 / Rakuten Aspyrian, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Integrated data review evaluating safety, pharmacokinetics (PK) and immunogenicity of RM-1929 photoimmunotherapy (PIT) in subjects with locoregional, recurrent head and neck squamous cell carcinoma (rHNSCC) (Poster Area (Hall 4)) - Sep 11, 2019 - Abstract #ESMO2019ESMO_2862;
P1/2
Clinical trial identification: NCT02422979. Legal entity responsible for the study: Rakuten Medical, Inc.
- Keytruda (pembrolizumab) / Merck (MSD), Erbitux (cetuximab) / Eli Lilly, EMD Serono
Phase III KEYNOTE-048 study of first-line (1L) pembrolizumab (P) for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Asia vs non-Asia subgroup (subgrp) analysis (Poster Area (Hall 4)) - Sep 11, 2019 - Abstract #ESMO2019ESMO_2861;
P3
P+C vs E showed favorable OS in pts with CPS ≥20 in Asia and non-Asia subgrps regardless of PD-L1 status, durable responses, and similar safety. Clinical trial identification: NCT02358031.
- monalizumab (IPH2201) / AstraZeneca, Innate, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Monalizumab in combination with cetuximab in patients (pts) with recurrent or metastatic (R/M) head and neck cancer (SCCHN) previously treated or not with PD-(L)1 inhibitors (IO): 1-year survival data (Poster Area (Hall 4)) - Sep 11, 2019 - Abstract #ESMO2019ESMO_2859;
P1b/2
An additional R/M SCCHN cohort of 40 patients who received both platinum-based chemotherapy and IO is being enrolled in this study. Clinical trial identification: NCT02643550.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, paclitaxel / Generic Mfg.
Treatment outcomes of head and neck cancer patients 70 years and older receiving different chemo-radiation combinations (Poster Area (Hall 4)) - Sep 11, 2019 - Abstract #ESMO2019ESMO_2851;
Single agent CB was associated with worse outcomes. CE seems to be related to a higher rate of long term PEG dependence.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Radiotherapy plus cisplatin (CDDP) or cetuximab (C225) in human papilloma-virus (HPV)-associated oropharyngeal cancer (OPC)? A dilemma finally resolved. An updated meta-analysis (Poster Area (Hall 4)) - Sep 11, 2019 - Abstract #ESMO2019ESMO_2850;
Further investigations are necessary in order to define optimal treatment in HPV-negative HNSCCs. Legal entity responsible for the study: Petar Suton.
- Ibrance (palbociclib) / Pfizer, Erbitux (cetuximab) / Eli Lilly, EMD Serono
A phase I study of the CDK4/6 inhibitor, palbociclib in combination with cetuximab and intensity modulated radiation therapy (IMRT) for locally advanced squamous cell carcinoma of the head and neck (SCCHN); A result of dose escalation cohort (Poster Area (Hall 4)) - Sep 11, 2019 - Abstract #ESMO2019ESMO_2848;
P1/2
MTD was not achieved. The combination was well tolerated with promising preliminary efficacy.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Detection of microRNAs as biomarker for anti-EGFR antibody resistance in colon cancer patients (Poster Area (Hall 4)) - Sep 11, 2019 - Abstract #ESMO2019ESMO_2704;
Further work is ongoing to characterize the molecular mechanisms underpinning let-7g mediated effect on anti-EGFR sensitivity in RAS wt CRC cells. Legal entity responsible for the study: The authors.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Evaluation of antibody-dependent cell cytotoxicity (ADCC) in lung cancer cell lines treated with combined anti-EGFR and anti-PD-L1 therapy (Poster Area (Hall 4)) - Sep 11, 2019 - Abstract #ESMO2019ESMO_2660;
Legal entity responsible for the study: Università degli studi della Campania Luigi Vanvitelli. Funding: Merck KGaA.
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Circulating-free DNA analysis from long-term surviving metastatic colorectal cancer patients undergoing surgery for resectable disease (Poster Area (Hall 4)) - Sep 11, 2019 - Abstract #ESMO2019ESMO_2640;
Moreover, this molecular analysis can help to subgroup patients with regard to risk of relapse after radical surgery. Indeed, cfDNA mutations present before surgery seem to be an indication for a higher risk of post-surgery disease relapse.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
AXL expression predicts poor prognosis and lack of efficacy of anti-angiogenic and anti-epidermal growth factor receptor (EGFR) agents in patients (pts) with RAS wild type (WT) metastatic colorectal cancer (mCRC) (Poster Area (Hall 4)) - Sep 11, 2019 - Abstract #ESMO2019ESMO_2549;
In RAS WT pts, AXL expression might represent a predictive biomarker of lack of efficacy for both anti-EGFR and anti-angiogenic agents. Legal entity responsible for the study: Department of Precision Medicine, Università degli Studi della Campania "Luigi Vanvitelli".